TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01269931

Intervention type: PROCEDURE
Intervention: EBUS-TBNA
Description: Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.

Intervention type: PROCEDURE
Intervention: EBUS-TBNA
Description: Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
Study: NCT02897245

Intervention type: OTHER
Intervention: No intervention
Study: NCT02227511

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fruits
Description: Randomization to extra fruit or nuts as snacks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nuts
Study: NCT02568839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel + trastuzumab sc + pertuzumab
Description: docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansin
Description: trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
Study: NCT04446923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hand antisepsis by scrub
Description: Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis by scrub
Description: Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
Study: NCT00875797

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: parenteral glutamine
Description: Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral glutamine
Description: Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered in accordance with local guidelines, prescribing information/summary of product
Study: NCT01519791

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
Study: NCT02882789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Description: Cohort1 \& 3: Placebo-controlled, Single ascending dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Description: Cohort1 \& 3: Placebo-controlled, Single ascending dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Description: Cohort1 \& 3: Placebo-controlled, Single ascending dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 400mg
Description: Cohort 2: Crossover designed administration
Study: NCT00733291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens
Description: Commercially marketed, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens
Description: Commercially marketed, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens
Description: Commercially marketed, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens
Description: Commercially marketed, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FID 107027 solution
Description: Commercially marketed solution for contact lens disinfection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FID 107027 solution
Description: Commercially marketed solution for contact lens disinfection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FID 107027 solution
Description: Commercially marketed solution for contact lens disinfection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FID 107027 solution
Description: Commercially marketed solution for contact lens disinfection
Study: NCT02352272

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Total Sleep deprivation
Description: Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Sleep deprivation
Description: Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
Study: NCT03721601

Intervention type: DEVICE
Intervention: Heart rate monitor chest strap
Description: Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.

Intervention type: DEVICE
Intervention: Heart rate monitor chest strap
Description: Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.

Intervention type: DEVICE
Intervention: Wrist band photoplethysmography
Description: Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.

Intervention type: DEVICE
Intervention: Wrist band photoplethysmography
Description: Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
Study: NCT01307007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: 15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Dextran Injection
Description: Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
Study: NCT01183156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Re-invitation letter
Description: Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
Study: NCT00848289

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
Study: NCT01183156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to educational meeting
Description: Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
Study: NCT02090244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
Study: NCT01447602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-A
Description: Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
Study: NCT01927367

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Decision Support System for AF
Description: A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
Study: NCT04372030

Intervention type: OTHER
Group type: OTHER
Intervention: Online questionnaire
Description: this is an online questionnaire collecting retrospective data on health care use and non-use
Study: NCT02375113

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soy supplementation
Description: Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy supplementation
Description: Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone.
Study: NCT03418415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: multi-electrode catheter-based renal denervation
Study: NCT04606082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulated Factor
Description: GCSF was intrauterine injected once at ovum pick up day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropins
Description: 500 IU of HCG was injected intrauterine once at ovum pick up day
Study: NCT01648205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be given for first month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Patients will receive ranolazine 1000mg bid for subsequent 5 months.
Study: NCT00477971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: No administration information given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV or orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Given on day 0
Study: NCT02882009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
Study: NCT03725280

Intervention type: PROCEDURE
Intervention: IVF
Description: None interventional study (Collection of ovarian follicular fluid during IVF treatment)

Intervention type: PROCEDURE
Intervention: IVF
Description: None interventional study (Collection of ovarian follicular fluid during IVF treatment)

Intervention type: PROCEDURE
Intervention: IVF
Description: None interventional study (Collection of ovarian follicular fluid during IVF treatment)

Intervention type: PROCEDURE
Intervention: IVF
Description: None interventional study (Collection of ovarian follicular fluid during IVF treatment)
Study: NCT00241280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galyfilcon A
Study: NCT00830596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVLA-SM
Description: High velocity, low amplitude lumbo-pelvic manipulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LVVA-SM
Description: Low velocity, variable amplitude lumbo-pelvic manipulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Intervention
Description: 2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
Study: NCT02876354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menaquinone
Description: Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
Study: NCT04689633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
Study: NCT01678677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838500A (formulation 1)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838501A (formulation 2)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838502A (formulation 3)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838503A (formulation 4)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838504A (formulation 5)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838505A (formulation 6)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT01678677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838508A (formulation 7)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838509A (formulation 8)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT03218072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: a potential rituximab biosimilar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: a potential rituximab biosimilar
Study: NCT03604991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03218072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: a potential rituximab biosimilar